Our new website provides a clear message of who we are, what we stand for and and how we invent, develop and apply the best analytical technologies for drug development and clinical research, and establish practical platforms for routine diagnosis.
The website also boasts a clean Scandinavian design and consistent site-wide search system with improved menu functionality. It is also fully responsive with mobile devices, making it easy to navigate on a wide range of web browsers and portable devices.
We will continue to introduce a range of new content to the website and build a knowledge repository for to help you make the right decisions about partnering up with us, our laboratory services or purchasing our products. We also plan to continue adding more content about how we can help to push the boundaries in drug discovery and clinical diagnostics and provide you with all of the information you need to evaluate our products and services.
We’re really proud of the new website and feel it will create the experience you’re looking for when you pay us a visit. Svar means answers in Swedish. If you have questions, we can help you find the right answers. Contact us today.
The Euro Diagnostica group of companies today announced a corporate rebrand to Svar Life Science. The companies formerly known as Euro Diagnostica AB and Wieslab AB are now operational as “Svar Life Science AB” and “Wieslab AB, a Svar Life Science company”. The rebranding consists of: a new corporate brand structure, a new slogan, and a new focus for the group.
As a global supplier and partner within drug discovery and clinical diagnostics, the Svar Life Science group of companies have more than 30 years of experience serving the life science market with products and laboratory services aimed at helping customers move forward in the drug development process.
The group will continue to find and harness the optimal solutions through mergers, acquisitions, in-house innovation, industry collaboration and knowledge exchange and the adoption of a new brand signifies new beginnings.
In Swedish Svar means answers and the brand reflects the evolution of the company, the vision for the future as well as a strong Scandinavian heritage and the attributes associated with it: reliability, quality, expertise, responsiveness and focus on people.
With this corporate rebranding, the Svar Life Science group of companies are strengthening their focus of delivering a full suite of products and services to life science companies which is reflected in the new tagline, "Answers in Life Science."
Ron Long, CEO, Svar Life Science, said:
“This rebrand represents a significant step in the company’s evolution and forms a part of our strategy of focusing our product portfolio and core technologies to deliver high quality solutions, the best analytical technologies and platforms for drug development, clinical research and routine diagnosis – answering to the needs in drug discovery and clinical diagnostics today.”
About Svar Life Science
Svar Life Science is a Swedish life science company that invents, develops and applies the best analytical technologies for drug development and clinical research, and establishes practical platforms for routine diagnosis. You can be sure of our answers: we’ve been working right across the clinical diagnostic value chain for over 30 years.
Svar is your partner for researching diagnostic strategies for personalized medicine and developing companion diagnostics based on assays customized for you. Once the assays are established, you can use us for dedicated testing in early discovery, preclinical and clinical phases. Our special competence areas are autoimmune disease, inflammatory disease and cancer, with a focus on IBD and RA.
Svar Life Science:
Jörgen Dahlström, Chief Business Officer
T +46 40 53 76 08
Wieslab AB, a Svar Life Science company
Michael Akoh, Vice President Laboratory Services
T +46 40 53 76 31
The new iLite® ADCC Activity Assay product line enables measurement of Antibody-dependent cell-medicated cytotoxicity (ADCC) in a straight forward, sensitive and reproducible manner. The new product line broadens Svar Life Sciences´ offering of cell-based assays and complement the product and service solutions already appreciated by pharmaceutical clients.
Jörgen Dahlström, Chief Business Officer, Svar Life Science, says:
"Antibody therapy has been proven to be highly powerful for cancer treatment and an important mechanism is the ability of antibody drugs to kill targeted tumour cells by Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). It is our aim to launch new and unique products within this field since the addition complements our existing assay solutions, and cements Svar Life Science position as a supplier of products and services for the pharma industry”.
The iLite® ADCC Activity Set contains 3 different genetically modified cell lines; a reporter Effector cell, a positive Target cell and a negative Target cell. All three products can be supplied individually or in combination as iLite® ADCC Activity Set. These Activity sets enables measurements of an anti-targeted drug’s ability to induce ADCC, does not require any cell culturing and allow results to be read within 4 hours. In addition, the Effector cells, which can be used with any Target cell, include a normalization readout which can be used to adjust for differences in cell counts.
Target cells for HER2. EGFR and membrane bound TNF- alpha will be the first to be launched, followed by shortly by CD20 Target cells.
“The unique set-up of Assay Ready effector cells and matched target cells, engineered to work optimally together, gives unparalleled sensitivity and with the launch of the first products in the iLite® ADCC product line, we can successfully assist clients with accelerating their drug discovery and development programs” adds Therese Segerstein, Product Manager Cell Based Assays.
As all iLite® cell lines, the ADCC products are provided as Assay Ready Cells and can be set up and performed through our bioanalytical service laboratory in compliance with GLP and GCP.
For further information please contact:
Product Manager Cell Based Assays
T +46 40 643 49 21
Senior Director Sales EMEA & APAC
T +46 40 53 76 11
Svar Life Science, is excited to launch a C4d Assay Kit. C4d can be used as a complement activity marker for the classical and lectin pathways and the assay is targeting a unique cleavage epitope on C4d, which means that only the C4d is measured.
The complement system plays an essential role in autoimmune and infectious diseases. There are three pathways of complement activation; the classical, the alternative and the lectin pathway.
The C4d protein is a product of the classical and the lectin pathways and now Svar Life Science has developed a C4d Elisa kit to measure C4d in human plasma.
The Svar Life Science complement C4d assay is a highly specific complement activity marker for the classical and lectin pathway.
The Svar C4d assay:
For a detailed description of this product please click here.